Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Veronica A Guerra"'
Autor:
Adam S. Sperling, Veronica A. Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang, Andrew T. Nguyen, Peter G. Miller, Marie E. McConkey, Vanessa A. Quevedo Barrios, Ken Furudate, Linda Zhang, Rashmi Kanagal-Shamanna, Jianhua Zhang, Latasha Little, Curtis Gumbs, Naval Daver, Courtney D. DiNardo, Tapan Kadia, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero, P. Andrew Futreal, Benjamin L. Ebert, Koichi Takahashi
Publikováno v:
Blood. 140:1753-1763
There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the
Publikováno v:
Therapeutic Advances in Hematology, Vol 10 (2019)
Adult acute lymphoblastic leukemia (ALL) has a poor overall survival compared with pediatric ALL where cure rates are observed in more than 90% of patients. The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has chan
Externí odkaz:
https://doaj.org/article/57ae1795c67544fd99ab1199cf9bd440
Autor:
Farhad Ravandi, Joseph D. Khoury, Ghayas C. Issa, Elias Jabbour, Steven M. Kornblau, Mehrnoosh Tashakori, Koichi Takahashi, Courtney D. DiNardo, Sanam Loghavi, Veronica A Guerra, Hagop M. Kantarjian, Tapan M. Kadia, Marina Konopleva, Naval Daver, Nicholas J. Short, Yasmin Alwash, Rashmi Kanagal-Shamanna
Publikováno v:
Am J Hematol
TP53 mutations in acute myeloid leukemia (AML) are associated with resistance to standard treatments and dismal outcomes. The incidence and prognostic impact of the emergence of newly detectable TP53 mutations over the course of AML therapy has not b
Autor:
Courtney D. DiNardo, Veronica A Guerra, Nicholas J. Short, Elias Jabbour, Zeev Estrov, Guillermo Montalban-Bravo, Danielle Hammond, Kiran Naqvi, Sherry Pierce, Naveen Pemmaraju, Hagop M. Kantarjian, Jorge Ramos-Perez, Gautam Borthakur, Rashmi Kanagal-Shamanna, Koji Sasaki, Marina Konopleva, Tapan M. Kadia, Naval Daver, Farhad Ravandi, Guillermo Garcia-Manero
Publikováno v:
Leukemia. 35:1494-1499
Autor:
Zeev Estrov, Danielle Hammond, R N Sherry Pierce, Courtney D. DiNardo, Tapan M. Kadia, Jorge Ramos-Perez, Koji Sasaki, Veronica A Guerra, Naveen Pemmaraju, Guillermo Garcia-Manero, Sanam Loghavi, Joseph D. Khoury, Paul Shilpa, Guillermo Montalban-Bravo, Farhad Ravandi, Marina Konopleva, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Naval Daver, Keyur P. Patel, Elias Jabbour, Koichi Takahashi, Gautam Borthakur, Kiran Naqvi
Publikováno v:
Blood. 136:26-29
INTRODUCTION: The current WHO definition requires presence of persistent absolute monocytosis for the diagnosis of chronic myelomonocytic leukemia (CMML). Oligomonocytic CMML (O-CMML), defined by presence of clinical and pathological features of CMML
Autor:
John Fredy Nieto Ríos, Lina María Serna Higuita, Juan David Vélez Rivera, Henry Armando Giraldo Salazar, Jhonathan Ferney Vélez Morales, Veronica Pérez Guerra, Laura Ramírez Cardona, Oscar Mauricio Yepes Grajales, Juan Ignacio Marín Zuluaga, Octavio Muñoz Maya, Oscar Santos Sánchez, Carlos Enrique Yepes, Juan Carlos Restrepo
Publikováno v:
Revista Colombiana de Gastroenterología, Vol 30, Iss 4 (2016)
Avances en la terapia inmunosupresora han revolucionado los resultados a largo plazo del trasplante de hígado, sin embargo esto ha incrementado la prevalencia de enfermedad renal crónica (ERC); existen algunos factores de riesgo asociados como el
Externí odkaz:
https://doaj.org/article/71bd27ffc3ef424b99f343fd9c04e5d1
Autor:
Nicholas J. Short, Musa Yilmaz, Ghayas C. Issa, Sanam Loghavi, Guillermo Garcia-Manero, Courtney D. DiNardo, Keyur P. Patel, Veronica A Guerra, Marina Konopleva, Naveen Pemmaraju, Elias Jabbour, Koichi Takahashi, Hagop M. Kantarjian, Gautam Borthakur, Farhad Ravandi, Maro Ohanian, Jorge E. Cortes, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Ahmad S. Alotaibi, Sherry Pierce, Bachar Samra, Sa A. Wang, Naval Daver, Michael Andreeff, Guilin Tang, Kapil N. Bhalla
Publikováno v:
Blood Cancer Discov
Despite promising results with FLT3 inhibitors (FLT3i), response durations remain short. We studied pretreatment and relapse bone marrow samples from patients with FLT3-mutated acute myeloid leukemia (AML) treated with FLT3i-based therapies (secondar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4fb143b5ed8bc3561421c4f02a577b
https://europepmc.org/articles/PMC7935111/
https://europepmc.org/articles/PMC7935111/
Autor:
Michael Andreeff, Zeev Estrov, Maria Rhona Pinsoy, Naval Daver, Yesid Alvarado, Naveen Pemmaraju, Marina Konopleva, Lianchun Xiao, Tapan M. Kadia, Farhad Ravandi, Hagop M. Kantarjian, Sherry Pierce, Alessandra Ferrajoli, Jorge E. Cortes, Guillermo Garcia-Manero, Gautam Borthakur, Mahesh Swaminathan, Mark J. Levis, Courtney D. DiNardo, Maro Ohanian, Veronica A Guerra, Elias Jabbour, William G. Wierda, Nitin Jain
Publikováno v:
Haematologica
FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-dose
Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy
Publikováno v:
Blood
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with increased mortality in patients with hematological malignancies, with increase rates between 33-37%. Vaccination against SARS-CoV-2 have shown eff
Autor:
Vinitha Mary Kuruvilla, Rita Maduike, Tianyu Cai, Guillermo Garcia-Manero, Marina Konopleva, Kiran Naqvi, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Kapil Saxena, Veronica A Guerra, Nicholas J. Short, Stefano Tiziani, Tushar D. Bhagat, Amit Verma, Naveen Pemmaraju, Elias Jabbour, Steven M. Kornblau, Gautam Borthakur, Hagop M. Kantarjian, Jan A. Burger
Publikováno v:
Blood. 136:31-32
Background: Malignant cells exploit cellular metabolism for their survival through various mechanisms. A significant dependency of malignant myeloid cells on glutamine metabolism has been demonstrated in vitro. Glutamine can be metabolized by glutami